New TB vaccine granted orphan drug status.

New TB vaccine granted orphan drug status.

Bibliographic Details
Main Authors:	Lang, T, Hill, A, Mcshane, H, Shah, R, Towse, A, Pritchard, C, Garau, M
Format:	Journal article
Language:	English
Published:	2005

Similar Items

Establishing a reasonable price for an orphan drug
by: Mikel Berdud, et al.
Published: (2020-09-01)

Towards new TB vaccines
by: Brazier, B, et al.
Published: (2020)

TB vaccines in clinical development
by: Ginsburg, A, et al.
Published: (2016)

TB vaccines in clinical development
by: Ginsberg, A, et al.
Published: (2016)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
by: Mcshane, H
Published: (2008)

TB vaccines in clinical development
by: McShane, H, et al.
Published: (2016)

Need for more TB vaccine field sites.
by: Mcshane, H
Published: (2009)

Development of Orphan Vaccines: An Industry Perspective
by: Jean Lang, et al.
Published: (1999-12-01)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
by: Whelan, K, et al.
Published: (2009)

Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.
by: Minassian, A, et al.
Published: (2011)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
by: Owiafe, P, et al.
Published: (2012)

TB vaccine development: where are we and why is it so difficult?
by: Wilkie, M, et al.
Published: (2014)

Progress and challenges in TB vaccine development
by: Voss, G, et al.
Published: (2018)

Implementation status of pharmacological studies in the development of orphan drugs
by: Saki Yokoshiki, et al.
Published: (2024-01-01)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
by: Pathan, A, et al.
Published: (2012)

NOW THE SOLUTION IS HERE – SOCIAL ASSISTANCE FOR ORPHANED CHILDREN: THE EXTENDED CHILD SUPPORT GRANT
by: Sipho Sibanda, et al.
Published: (2023-04-01)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
by: Pathan, A, et al.
Published: (2012)

A review of clinical models for the evaluation of human TB vaccines.
by: O'Shea, M, et al.
Published: (2016)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
by: Kathryn T Whelan, et al.
Published: (2009-06-01)

Current status and trend of clinical development of orphan drugs in China
by: Ziling Xiang, et al.
Published: (2022-07-01)

Advances in orphan drug development: Time to change the status and stereotype
by: Sayanta Thakur
Published: (2022-01-01)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
by: Ewa Stawowczyk, et al.
Published: (2019-11-01)

Preeclampsia – will Orphan Drug Status facilitate innovative biological therapies?
by: Sinuhe eHahn
Published: (2015-02-01)

Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
by: Morrell, L, et al.
Published: (2017)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
by: Kathryn T. Whelan, et al.
Published: (2011-01-01)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
by: Odutola, A, et al.
Published: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
by: Odutola, A, et al.
Published: (2012)

Orphan drugs and rare diseases /
by: Pryde, David C., editor, et al.
Published: (2014)

Donor investment choices in developing countries: a methodology and some illustrative results based on Public-Private partnerships for product development (PD PPPs)
by: Gray, A, et al.
Published: (2007)

Current Status and Prospect of Orphan Drugs for Rare Skin Diseases in China
by: ZHANG Shan, et al.
Published: (2023-04-01)

Mechanism of coordinated access to orphan drugs
by: DeRidder R, et al.
Published: (2012-11-01)

FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development
by: Kathleen L. Miller, et al.
Published: (2020-09-01)

Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
by: Liz Morrell, et al.
Published: (2017-08-01)

A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data.
by: McShane, H, et al.
Published: (2014)

A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data
by: McShane, H, et al.
Published: (2014)

Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.
by: Angela M Minassian, et al.
Published: (2011-01-01)

Rare diseases and orphan drugs.
by: Aronson, J
Published: (2006)

Rare diseases and orphan drugs
by: Domenica Taruscio, et al.
Published: (2011-01-01)

Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
by: Hans-Georg Eichler, et al.
Published: (2023-01-01)

Expenditure trends of orphan drugs in Serbia: 8-Year analysis of orphan drug market in Serbia
by: Pejčić Ana V., et al.
Published: (2016-01-01)